Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Ulotaront in Schizophrenia
NCT04109950Phase 3Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Nov 2019
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of ulotaront in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Nov 2019; status: terminated.
02
Drugs
ulotaront
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04109950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04109950.